Építés alatt – nem éles oldal
Belépés
Befejeződött2/3. fázis

STRIDES - A Clinical Research Study of an Investigational New Drug to Treat Spinocerebellar Ataxia

A legfontosabb adatok

Ki végzi
Seelos Therapeutics Inc.
Hol
Németország, Portugália és Spanyolország8 helyszín, 3 országbanVálassz országot a helyszínekhez
Állapot
Befejeződött
Fázis
2/3. fázis
Résztvevők
58 fő vett részt
Kezdés
2023. jan. 30.
Befejezés
2024. febr. 12.
A vizsgálat típusa
Beavatkozással járó
A regiszteradat frissítve
2023. március 10.

Ki vehet részt

Életkor
18 év felett
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 24 feltétel megnézéseKevesebb

Ki vehet részt

  • Signed informed consent
  • Men and women, 18 to 75 years (inclusive) of age
  • Clinical diagnosis of SCA3 with documented genetic confirmation
  • m-SARA total score ≥ 4 at the screening visit
  • m-SARA gait component score ≥ 1 at the screening visit
  • Body Mass Index (BMI) between 18 kg/m2 and 35 kg/m2 (inclusive)
  • Stable doses of all concomitant medications for at least 30 days prior to the screening visit
  • Negative serum beta-human chorionic gonadotropin (ß-hCG) pregnancy result at the screening visit for female participants of childbearing potential
  • Willingness to comply with sexual abstinence or contraception guidelines of this study

Ki nem vehet részt

  • Current participation in another clinical trial or completed participation in an interventional trial less than 30 days prior to the screening visit (90 days for a biological treatment)
  • Prior treatment with SLS-005, any other IV trehalose formulation, or known hypersensitivity to trehalose
  • Any hereditary ataxia that is not genetically confirmed to be SCA Type 3, or any type of ataxia that is acquired or secondary to another medical condition including but not limited to, alcoholism, head injury, multiple sclerosis, olivopontocerebellar atrophy, multiple system atrophy, or stroke
  • Any current cardiovascular disease or abnormality on 12-lead ECG at screening that, in the investigator’s opinion, is clinically significant and could be a potential safety risk to the participant
  • Any current psychiatric, neurological, or cognitive disorder that, in the investigator’s opinion, may interfere with the participant’s ability to provide informed consent or appropriately complete the study’s safety or efficacy assessments
  • Any other medical condition or abnormal finding at screening that, in the investigator’s opinion, could confound collection or interpretation of safety or efficacy data or be a potential safety risk to the participant
  • Current diagnosis and/or healthcare professional-recommended treatment (medication and/or diet) of diabetes mellitus type 1 or type 2
  • History of alcohol or drug abuse within the last 2 years
  • Chronic liver disease including Hepatitis B; Hepatitis C unless successful curative treatment is documented; HIV infection
  • Prior history of drug-induced liver injury (DILI) and/or laboratory results at screening that indicate inadequate liver function (e.g. alanine aminotransferase [ALT], aspartate aminotransferase [AST], gamma-glutamyl transferase [GGT] > 2 times the upper limit of normal [x ULN] and/or total bilirubin level > 2 x ULN)
  • Laboratory results at screening that indicate inadequate renal function (e.g. estimated creatinine clearance of < 60 mL/min calculated by the Cockcroft and Gault formula)
  • Hemoglobin A1c (HbA1c) ≥ 6.5% at the screening visit
  • Significant suicide risk as indicated by a “yes” response to question #4 or #5 under Suicidal Ideation in the past 6 months or any “yes” response under Suicidal Behavior in the past 3 years on the Columbia Suicide Severity Rating Scale (C-SSRS) during the screening visit
  • A score of 4 on any 1 of the 4 items that comprise the m-SARA
  • Pregnant or breastfeeding

Hol van ez a vizsgálat?

3 országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

Determine the efficacy of SLS-005 0.75 g/kg for the treatment of spinocerebellar ataxia type-3 (SCA3) in adults

Adatok és források

Regiszteradat
Szerepel az EU hivatalos vizsgálati nyilvántartásában (CTIS).
Hivatalos cím
A DOUBLE-BLIND, RANDOMIZED, PLACEBO CONTROLLED TRIAL TO ASSESS SAFETY AND EFFICACY OF SLS-005 (TREHALOSE INJECTION, 90.5 MG/ML FOR INTRAVENOUS INFUSION) FOR THE TREATMENT OF ADULTS WITH SPINOCEREBELLAR ATAXIA
A regiszteradat frissítve
2023. március 10.